ResearcherHokkaido UniversityNo recent work listed
Shintaro Nakano
Matched on ORCID iD 0000-0001-9630-572X; OpenAlex author ID A5001876291. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper
Papers 6
- Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pa… Co-author DOI 10.3390/jcm12041596↗
- Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples. Co-author DOI 10.1097/mpa.0000000000002028↗
- Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan… Co-author DOI 10.1136/bmjopen-2021-048833↗
- A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Co-author DOI 10.1002/onco.13838↗
- Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally Advanced Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-356113/v1↗
- Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000022250↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yoshito Komatsu · 6 shared papers, 2020–2023 · strength 0.74
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1↗
- Paper Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cance… DOI 10.1097/md.0000000000022250↗
- Yasuyuki Kawamoto · 6 shared papers, 2020–2023 · strength 0.74
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1↗
- Paper Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cance… DOI 10.1097/md.0000000000022250↗
- Kazuaki Harada · 5 shared papers, 2021–2023 · strength 0.62
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Naoya Sakamoto · 5 shared papers, 2020–2023 · strength 0.61
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cance… DOI 10.1097/md.0000000000022250↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Tetsuhito Muranaka · 2 shared papers, 2021–2023 · strength 0.26
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Yuh Sakata · 2 shared papers, 2022–2023 · strength 0.26
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination c… DOI 10.1136/bmjopen-2021-048833↗
- Naoya Sakamoto · 1 shared paper, 2021 · strength 0.13
- Hideyuki Hayashi · 1 shared paper, 2021 · strength 0.12
- Atsushi Satō · 1 shared paper, 2022 · strength 0.12
- Yunosuke Takishin · 1 shared paper, 2022 · strength 0.12
- Masaki Kuwatani · 1 shared paper, 2022 · strength 0.12
- Kazumichi Kawakubo · 1 shared paper, 2022 · strength 0.12
- Ryo Sugiura · 1 shared paper, 2022 · strength 0.12
- Shin Kato · 1 shared paper, 2022 · strength 0.12
- Shinya Kajiura · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.